SCHEMBL113393

SCHEMBL113393

CCCCOC(=O)C(N)CS

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
ATM Q13315 1/20 0.45
TSHR P16473 6/20 0.42
HPGD P15428 1/20 0.42
PTGS1 P23219 1/20 0.41
SLC7A11 Q9UPY5 1/20 0.41
HCAR2 Q8TDS4 1/20 0.40
NOD1 Q9Y239 1/20 0.40
LMNA P02545 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
PDE4D Q08499 1/20 0.40
NAAA Q02083 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL113394 1.00 ALDH1A1 (0.48) ALDH1A1ATMTSHRHPGDPTGS1
SCHEMBL25179254 0.98 ALDH1A1 (0.47) ALDH1A1ATMTSHRHPGDPTGS1
Hydrochloric Acid SCHEMBL9588194 0.98 ALDH1A1 (0.47) ALDH1A1ATMTSHRHPGDPTGS1
SCHEMBL1063905 0.94 NAAA (0.47) ALDH1A1TSHRPTGS1SLC7A11HCAR2
SCHEMBL5220076 0.92 NAAA (0.50) ALDH1A1TSHRHCAR2NOD1LMNA
Hydrochloric Acid SCHEMBL9588157 0.92 NAAA (0.46) ALDH1A1TSHRHCAR2NOD1CYP3A4
SCHEMBL112307 0.92 NAAA (0.50) ALDH1A1TSHRHCAR2NOD1LMNA
SCHEMBL25183414 0.92 NAAA (0.46) ALDH1A1TSHRPTGS1SLC7A11HCAR2
SCHEMBL114444 0.92 NAAA (0.50) ALDH1A1TSHRHCAR2NOD1LMNA
SCHEMBL110652 0.92 NAAA (0.50) ALDH1A1TSHRHCAR2NOD1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024026124-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF PETERSON MATTHEW (US) 2024-02-01 WO claimed
CN-102802605-A Stable lipid formulations of apoptosis promoters ABBOTT LAB 2012-11-28 CN claimed
EP-2424499-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER Abbott Laboratories (US) 2012-03-07 EP claimed
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBVIE INC. 2010-11-04 US claimed
WO-2010127193-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBOTT LABORATORIES (US) 2010-11-04 WO claimed
JP-4139203-A None JP disclosed
WO-2024026124-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF PETERSON MATTHEW (US) 2024-02-01 WO disclosed
WO-2023067123-A1 OLIGOSACCHARIDE COMPLEXES AND USES BioNTech SE (DE) 2023-04-27 WO disclosed
US-9758688-B2 Composition for forming conductive film SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-09-12 US disclosed
CN-105820138-A ABT-263 crystalline forms and solvates for use in treating BCL-2 protein related diseases ABBVIE 公司 2016-08-03 CN disclosed
CN-102655858-B ABT-263 capsule ABBVIE (US) 2015-11-25 CN disclosed
US-20150275015-A1 COMPOSITION FOR FORMING CONDUCTIVE FILM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-10-01 US disclosed
WO-2010127198-A1 FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER ABBOTT LABORATORIES (US) 2010-11-04 WO disclosed
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBVIE INC. 2010-11-04 US disclosed
WO-2010127193-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBOTT LABORATORIES (US) 2010-11-04 WO disclosed
WO-2010127190-A1 SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF ABBOTT LABORATORIES (US) 2010-11-04 WO disclosed
EP-0546063-A1 TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND USES The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) 1993-06-16 EP disclosed
JP-H04139203-A MACROMONOMER KURARAY CO LTD 1992-05-13 JP disclosed
WO-1992004024-A2 TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND METHOD THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1992-03-19 WO disclosed
EP-0421296-A2 Polyvinyl ester macromonomer and its uses KURARAY CO., LTD. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER BCL2, BAX, BCOR ALDH1A1 3985/4885ATM 2737/4885TSHR 4319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.